PPH Summit 2019
>2019 Agenda
Powering Precision Health Summit
2019 Agenda
November 19, 2019
Barcelona, Spain
Hotel Miramar
| Neurology Track | Oncology Track | |
| 8:30 AM | Welcome, Agenda & Opening Keynote “Vision to Reality: Disrupting Healthcare with Digital Biomarkers” Kevin Hrusovsky, Founder & Chairman, Powering Precision Health; CEO, President, and Chairman, Quanterix |
|
| 9:10 AM | Fireside Chat with Theranos Whistleblower “Fraud is Not a Trade Secret” Tyler Shultz, CEO Flux Biosciences Inc and Kevin Hrusovsky PPH Founder and CEO, Quanterix |
|
| 9:30 AM | Neurofilament Light Hot Topics Professor David Leppert, University Hospital of Basel |
Ultra-Sensitive Immunoassays for Biomarker Analysis in Clinical Samples Dr. Thomas Joos, NMI |
| 9:45 AM | Endophenotypes of Traumatic Brain Injury: What We Need to Know for the Next Generation of Clinical Trials in TBI Dr. Ramon Diaz-Arrastia, University of Pennsylvania |
Clinical Bioanalytical Testing Strategies of bispecific Cancer Immunotherapeutics Dr. Gregor Lotz, Roche |
| 10:00 AM | Blood NFL in brain trauma, sports concussion, and acute brain disorders Dr. Kaj Blennow, University of Gothenburg |
Nu.Q™-Capture – Enabling complete nucleosome profiling Dr. Marc Eccleston, Volition |
| 10:15 AM | pTau181:The Next NfL? Professor Henrik Zetterberg, University of Gothenburg |
Industry perspectives on context of use and Biomarker assays Dr. John Smeraglia, UCB BioPharma |
| 10:30 AM | Coffee Break | |
| 10:45 AM | Can we rely on Serum NfL in Multiple Sclerosis Management in the Future? Dr. Jens Kuhle, University Hospital of Basel |
Practical Considerations of Using Ultra-Sensitive Single and Multiplex Biomarkers for Precision Medicine Dr. Maribeth Raines, MBBB Solutions |
| 11:00 AM | Neurofilament light chain: A new candidate biomarker in hATTR amyloidosis Dr. Simina Ticau, Alnylam Pharmaceuticals |
Cytokines and Chemokines in the Cross-Talk Between Cancer Cells and the Immune System Professor Rudolf Oehler, Medical University of Vienna |
| 11:15 AM | Developing novel measurement tools and structured analytical data models to improve patient management decisions, create better outcomes and lower costs in MS William Hagstrom, Octave BioSciences |
Detection of type I interferons by Digital ELISA: applications in clinical and pre-clinical research Dr. Mathieu Rodero, Université Paris Descartes |
| 11:30 AM | Developing a clinical/IVD NF-L assay for worldwide patient access Dr. Andrew Beard, Siemens Healthineers |
Type I interferon in Viral infections and interferonopathies Dr. Sophie Trouillet-Assant, CHU Lyon |
| 11:45 PM | EXPERT PANEL DISCUSSION “How can we accelerate moving Nf-L from Research to Clinic?” Dr. Jens Kuhle, University Hospital of Basel Dr. Mark Frasier, Michael J. Fox Foundation William Hagstrom, Octave BioSciences Professor David Leppert, University Hospital of Basel Dr. Andrew Beard, Siemens Healthineers Dr. Sara Mariotta, University of Verona, Italy Moderator: Kevin Hrusovsky, PPH Founder and CEO, Quanterix |
EXPERT PANEL DISCUSSION “Where will protein biomarkers take us in Oncology?” Dr. Maribeth Raines, MBBB Solutions Professor Rudolf Oehler, Medical University of Vienna Dr. Mathieu Rodero, Université Paris Descartes Dr. Steven Piccoli, GlaxoSmith Kline Moderator: Dr. Mark Roskey, Quanterix |
| 12:30 PM | Lunch – Moderated Thematic Discussions | |
| 1:30 PM | Plasma Amyloid, GFAP and NfL as Predictors of Alzheimer’s Pathology Professor Elisabeth Thijssen, Amsterdam UMC |
Urine as a non-invasive source of biomarkers for the screening, diagnosis and prognosis of prostate cancer Dr. Irina Banzola, University Hospital Zurich |
| 1:45 PM | Accelerating New Treatments and Biomarkers for Parkinson’s Disease through Novel Collaborations Dr. Mark Frasier, Michael J. Fox Foundation |
Genomics, Schenomics! Proteins Are the Cornerstone of Precision Medicine! Dr. Steve Piccoli, GlaxoSmith Kline |
| 2:00 PM | Real World Experience with Nf-L in MS Patients Dr. Rany Aburashed, Memorial Healthcare Hospital |
SU2C Patient Advocacy – From Premise to Promise Renee Nicholas, Stand up to Cancer |
| 2:15 PM | Enabling Clinical Trials of Disease-modifying Therapies for Huntington’s Disease: The Ultrasensitive Detection Revolution Dr. Lauren Byrne, University College London |
Oncology byte-sized: moving towards 3bn data points, 1 decision Dr. Laure-Anne Ventouras, McKinsey Consulting |
| 2:30 PM | Late-Breaking Results from Mass Spectrometry-based Amyloid Beta Test for Alzheimer’s Disease Dr. Joel Braunstein, C2N Diagnostics |
Detecting and targeting altered stroma to prevent and/or treat metastatic disease Dr. Ellen Puré, University of Pennsylvania |
| 2:45 PM | Investigating Alpha-synuclein as a Biomarker for Parkinson’s Disease Professor Deniz Kirik, Lund University |
Biomarkers – Ideal, reality and future Dr. Stephanie Traub, Centre for Drug Development at Cancer Research UK |
| 3:00 PM | Coffee Break | |
| 3:15 PM | Expert Panel Discussion “Challenges and Opportunities for Blood Tests for Alzheimer’s, MS, Parkinson’s, and ALS” Dr. Jens Kuhle, University Hospital of Basel Professor Elisabeth Thijssen, Amsterdam UMC Professor Henrik Zetterberg, University of Gothenburg Dr. Mark Frasier, Michael J. Fox Foundation Dr. Rany Aburashed, Memorial Healthcare Hospital Dr. Simina Ticau, Alnylam Pharmaceuticals Moderator: Kevin Hrusovsky, PPH founder and CEO, Quanterix |
|
| 3:45 PM | “Precision Health in China: Growing market, changing society, and future medical needs” Dr. Sen Liu, Secretary General, China Neurodegenerative Disease Association |
|
| 4:00 PM | Should microglial activation be a therapeutic target in Alzheimer’s disease? Professor Robert Perneczky, LMU Munich |
One Parents Perspective on the Promise of Precision Medicine for Pediatric Oncology Patrick Sullivan, Childhood Cancer Canada |
| 4:15 PM | Serum NfL as Predictor of Visual Outcome After Optic Neuritis Dr. Roberto Furlan, San Rafaele Scientific Institute |
Predictive biomarkers to guide anti-angiogenic therapy: the search continues Dr. Andrew Nixon, Duke University |
| 4:30 PM | Reverse phase protein array (RPPA) in traumatic brain injury research; the power of flexibility and throughput in discovering pathomechanisms and biomarkers Dr. Denes Agoston, Uniformed Health Services |
Personalizing checkpoint inhibitor-based cancer immunotherapy Dr. Justin Balko, Vanderbilt University |
| 4:45 PM | Antibody Development & Detection Technology Innovation — Collaborations Models to Power Precision Health Koen Dewaele, ADx Neurosciences |
The role of multi-omic profiling for treatment selection in metastatic breast cancer Dr. Mariaelena Pierobon, George Mason University |
| 5:00 PM | The Immune Response as Surrogate Biomarker of Neurodegeneration: The Example of ALS Dr. Andrea Malaspina, University of London |
Multi-omic molecular tumor boards: choosing tests and implementation into clinical practice Dr. Ari VanderWalde, West Cancer Center |
| 5:15 PM | EXPERT PANEL DISCUSSION “Applying Digital Protein Biomarkers to Oncology & Immuno-Oncology: Is the time now?” Dr. Andy Nixon, Duke University Dr. Justin Balko, Vanderbilt University Dr. Mariaelena Pierobon, George Mason University Dr. Ari VanderWalde, West Cancer Center Patrick Sullivan, Childhood Cancer Canada Moderator: Kevin Hrusovsky, PPH Founder and CEO, Quanterix |
|
| 5:45 PM | Closing Comments Kevin Hrusovsky, Powering Precision Health |
|
| 6:00 PM | PPH Celebration & Cocktail Reception, All Welcome! | |
Missed this years event? Watch our videos on YouTube or on our Videos Page
Missed last years event? Enjoy the streamed version of the event on Periscope